Immatics N.V.
IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecificsā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.66
Price-5.87%
-$0.54
1Y
Price
Market Cap
$1.161b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.-913.4%
EBITDA Margin-974.5%
Net Profit Margin-882.7%
Free Cash Flow Margin-913.4%
EBITDA Margin-974.5%
Net Profit Margin-882.7%
Free Cash Flow MarginRevenue
$37.297m
-45.6%
1y CAGR+24.7%
3y CAGR+117.9%
5y CAGREarnings
-$214.405m
-861.5%
1y CAGR-368.1%
3y CAGR-241.2%
5y CAGREPS
-$1.71
-721.4%
1y CAGR-310.7%
3y CAGR-199.1%
5y CAGRBook Value
$456.276m
$543.831m
Assets$87.554m
Liabilities$15.097m
DebtDebt to Assets
2.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$188.490m
-5.4%
1y CAGR-463.3%
3y CAGR-295.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company